Blockchain Registration Transaction Record

Okogen Gets CDSCO Nod for Treyegen™ Phase 1/2 Conjunctivitis Study

Okogen wins CDSCO authorization for EMERALD Phase 1/2 trial of Treyegen™ (OKG-0303) in acute infectious conjunctivitis, enrolling 300+ patients in India.

This news matters because acute infectious conjunctivitis, commonly known as pink eye, is a highly contagious condition that affects millions of people annually, leading to significant discomfort, missed work and school days, and substantial healthcare costs. Current treatments often require guesswork because clinicians must determine whether the infection is viral or bacterial before prescribing, and there is no single therapy that addresses both. Treyegen™ (OKG-0303) could change that paradigm by offering a single formulation that targets both types of infection while also reducing redness. If successful, this therapy could streamline treatment, improve patient outcomes, and reduce the overuse of antibiotics. Moreover, the CDSCO authorization validates Okogen's host-directed antiviral platform and opens the door to further clinical development in a populous country with a high burden of infectious diseases. The EMERALD study's data, expected later this year, will be closely watched as a potential breakthrough in ophthalmology and as a proof of concept for ranpirnase across other therapeutic areas.